Learn how GA4GH helps expand responsible genomic data use to benefit human health.
Learn how GA4GH helps expand responsible genomic data use to benefit human health.
Our Strategic Road Map defines strategies, standards, and policy frameworks to support responsible global use of genomic and related health data.
Discover how a meeting of 50 leaders in genomics and medicine led to an alliance uniting more than 5,000 individuals and organisations to benefit human health.
GA4GH Inc. is a not-for-profit organisation that supports the global GA4GH community.
To guide our collaborative, globe-spanning alliance, GA4GH relies on a Standards Steering Committee and an Executive Committee.
The Funders Forum brings together organisations that offer both financial support and strategic guidance.
The EDI Advisory Group responds to issues raised in the GA4GH community, finding equitable, inclusive ways to build products that benefit diverse groups.
Distributed across four Host Institutions, our staff team supports the mission and operations of GA4GH.
Curious who we are? Meet the people and organisations across six continents who make up GA4GH.
More than 500 organisations connected to genomics — in healthcare, research, patient advocacy, industry, and beyond — have signed onto the mission and vision of GA4GH as Organisational Members.
These core Organisational Members are genomic data initiatives that have committed resources to guide GA4GH work and pilot our products.
This subset of Organisational Members whose networks or infrastructure align with GA4GH priorities has made a long-term commitment to engaging with our community.
Local and national organisations assign experts to spend at least 30% of their time building GA4GH products.
Anyone working in genomics and related fields is invited to participate in our inclusive community by creating and using new products.
Wondering what GA4GH does? Learn how we find and overcome challenges to expanding responsible genomic data use for the benefit of human health.
Study Groups define needs. Participants survey the landscape of the genomics and health community and determine whether GA4GH can help.
Work Streams create products. Community members join together to develop technical standards, policy frameworks, and policy tools that overcome hurdles to international genomic data use.
GIF solves problems. Organisations in the forum pilot GA4GH products in real-world situations. Along the way, they troubleshoot products, suggest updates, and flag additional needs.
NIF finds challenges and opportunities in genomics at a global scale. National programmes meet to share best practices, avoid incompatabilities, and help translate genomics into benefits for human health.
Communities of Interest find challenges and opportunities in areas such as rare disease, cancer, and infectious disease. Participants pinpoint real-world problems that would benefit from broad data use.
Find out what’s happening with up to the minute meeting schedules for the GA4GH community.
See all our products — always free and open-source. Do you work on cloud genomics, data discovery, user access, data security or regulatory policy and ethics? Need to represent genomic, phenotypic, or clinical data? We’ve got a solution for you.
All GA4GH standards, frameworks, and tools follow the Product Development and Approval Process before being officially adopted.
Learn how other organisations have implemented GA4GH products to solve real-world problems.
Help us transform the future of genomic data use! See how GA4GH can benefit you — whether you’re using our products, writing our standards, subscribing to a newsletter, or more.
Help create new global standards and frameworks for responsible genomic data use.
Align your organisation with the GA4GH mission and vision.
Want to advance both your career and responsible genomic data sharing at the same time? See our open leadership opportunities.
Join our international team and help us advance genomic data use for the benefit of human health.
Share your thoughts on all GA4GH products currently open for public comment.
Solve real problems by aligning your organisation with the world’s genomics standards. We offer software dvelopers both customisable and out-of-the-box solutions to help you get started.
Learn more about upcoming GA4GH events. See reports and recordings from our past events.
Speak directly to the global genomics and health community while supporting GA4GH strategy.
Be the first to hear about the latest GA4GH products, upcoming meetings, new initiatives, and more.
Questions? We would love to hear from you.
Read news, stories, and insights from the forefront of genomic and clinical data use.
Attend an upcoming GA4GH event, or view meeting reports from past events.
See new projects, updates, and calls for support from the Work Streams.
Read academic papers coauthored by GA4GH contributors.
Listen to our podcast OmicsXchange, featuring discussions from leaders in the world of genomics, health, and data sharing.
Check out our videos, then subscribe to our YouTube channel for more content.
View the latest GA4GH updates, Genomics and Health News, Implementation Notes, GDPR Briefs, and more.
Discover all things GA4GH: explore our news, events, videos, podcasts, announcements, publications, and newsletters.
11 Mar 2022
This GA4GH Community Post is the tenth in our series featuring individuals from across our organization. This month we are turning the spotlight on Michael Baudis!
This GA4GH Community Post is the tenth in our series featuring individuals from across our organization. This month we are turning the spotlight on Michael Baudis! Baudis is a Professor of Bioinformatics at the Institute of Molecular Life Sciences, University of Zurich, and a group leader at the Swiss Institute of Bioinformatics. Michael studied Medicine at Heidelberg University, from which he graduated in 1998 and received his German medical license after internships at Heidelberg University Hospital. He received his doctorate from the Medical Faculty of the Ruprecht-Karls Universität Heidelberg in 1999. Since its founding in 2014, Michael has been a member of the Global Alliance for Genomics and Health (GA4GH), currently serving in the steering committee and as co-lead of the Discovery Work Stream. Baudis also co-chairs the ELIXIR Beacon project, which develops APIs to query genomic data collections in a privacy-protecting manner.
How did you get involved with GA4GH?
For more than a decade, my group at the University of Zürich and the Swiss Institute of Bioinformatics (SIB) has participated in the use and sharing of genomic and associated data from cancer profiling studies. We are both “data parasites” – for our own research – as well as resource providers, which share the curated data through our “Progenetix” project. While constantly updating our data collection – which currently contains more than 130,000 cancer-associated genome profiles – we became increasingly aware of the barriers to a truly comprehensive representation of cancer genomics data. Therefore, when in 2013, the Swiss Institute of Bioinformatics became one of the first organizations to join GA4GH; I immediately saw an opportunity to participate in this endeavour.
What current projects are you working on/what is your research focused on?
My research has somehow always revolved around cancer genomics, specifically the analysis of structural genome aberrations with a focus on copy number variations. Here, my group tries to understand the recurring mutation patterns observed across all different types of malignancies and to find connections between such patterns and diagnostic, clinical and other annotations – even involving geographic provenance or population background. Chiefly due to the work in a variety of GA4GH related projects, I now spend a considerable amount of time working on the development and implementation of data standards and protocols such as the Beacon API.
How does interoperability/data sharing help your work and its importance?
At this point, we don’t see too many benefits for the core data we’re using in our own studies – genomic profiling data and associated annotations still come in various formats and frequently have to be processed or converted with custom bioinformatics pipelines. However, two areas where we start to make use of GA4GH community output are the rapid improvement of annotated genomic variations as well as the emerging standards and tools we use to share our own data with cancer genomics communities.
The biggest impact on our research comes from the direct participation in GA4GH projects and constant interaction with experts from many different domains. The learning curve has been steep but led to deep changes in some of the ways we address projects and highly increased our interactions with international research communities, away from custom formats and workflows and towards a more active exchange of data and knowledge.
What scientific discovery throughout history is most fascinating to you?
That is a tricky one. Working in life sciences, I’m ought to say “Darwin’s theory of evolution by natural selection” – however, this is a way to understand the living world, based on meticulous studies and reasoning. So, maybe general relativity – especially since Albert Einstein graduated from the University of Zurich…
What is your favourite thing about the GA4GH Community and why?
What I love most is the combination of voluntary contributions by its members combined with very flat hierarchies and softly but expertly guided GA4GH’s administrative staff. Well known, world-class researchers closely interact with junior scientists, students, tech company CEOs and employees as well as data curators, from very different areas; I’m not aware of another place in life sciences where something like this happens – ELIXIR in some aspects comes close but then also has quite a bit of overlap & collaboration with GA4GH.
What is your favourite GA4GH event, and why?
This is a bit hard to say these days – but I would pick GA4GH Connect, since this is more of a “working event”, compared to the plenary.
Why is diverse global representation critical to advancing progress in the field?
Our research addresses the relation between mutational patterns in cancers with disease types, clinical and environmental parameters as well as inherited genetic variations. Our assessment of e.g. the geographic provenance of available studies and of the cancer genomic publication landscape, in general, has shown us extreme biases, e.g. with a current near-total absence of such studies from the African continent or Central Asia. Here, we may miss out on specific cancer biologies – influenced by specific lifestyles, environmental exposures or genetically modified disease risk – which otherwise could help us in detecting “new” biologies and potentially improve outcomes for the affected patients.
What advice would you give to individuals seeking to get more involved with GA4GH?
I think the biggest impact and satisfaction of being a part of the GA4GH community comes from working on something which informs and influences an area you love as a researcher, and where advances directly impact your own work. These improvements – of standards, protocols, data or research methods – may not necessarily have an impact on the outcomes of your ongoing research projects; but your contributions as an expert will be most productive when informed by work you’re deeply involved in. Also: Don’t be shy to propose, discuss, contribute – GA4GH groups are very open & welcoming!
How do you think genomic data standards will shape the world in 20 years?
With improved genomic data standards and exchange protocols – and based on the expectation that genomic analyses become “commodity” procedures – many new biomedical and consumer-oriented applications will see the light of day. For the next decade, I expect some groundbreaking shifts in the diagnosis of rare diseases and oncology, a move towards diagnoses and therapies becoming much more tailored to molecular observations than to summary diagnoses.
However, such advances are threatened through the broad use of “black box” diagnostics by point-of-care providers, and on a broader level by potential abuse of genomic tools and data for non-medical usage scenarios – think about the misconstrued genomic determinism and pervasive personal identification in “Gattaca”-like scenarios. The creation of genomic standards provides the groundwork for more powerful genomics research; the benefits depend a lot on a continuous dialogue with scientists, medical service providers, politicians and the society at large.